The TREAT Asia HIV observational database - Baseline and retrospective data

被引:128
作者
Zhou, J
Kumarasamy, N
Ditangco, R
Kamarulzaman, A
Lee, CKC
Li, PCK
Paton, NI
Phanuphak, P
Pujari, S
Vibhagool, A
Wong, WW
Zhang, F
Chuah, J
Frost, KR
Cooper, DA
Law, MG
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[2] YRG Ctr AIDS Res & Educ, Madras, Tamil Nadu, India
[3] Res Inst Trop Med, Manila, Philippines
[4] Univ Malaya, Kuala Lumpur, Malaysia
[5] Hosp Kuala Lumpur, Kuala Lumpur, Malaysia
[6] Queen Elizabeth Hosp, Hong Kong, Hong Kong, Peoples R China
[7] Tan Tock Seng Hosp, Singapore, Singapore
[8] HIV NAT Thai Red Cross AIDS Res Ctr, Bangkok, Thailand
[9] Ruby Hall Clin, HIV Project, Pune, Maharashtra, India
[10] Ramathibodi Hosp, Bangkok, Thailand
[11] Natl Yang Ming Univ, AIDS Prevent & Res Ctr, Taipei 112, Taiwan
[12] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Taipei 112, Taiwan
[13] Beijing Ditan Hosp, Beijing, Peoples R China
[14] Gold Coast Sexual Hlth Clin, Miami, Qld, Australia
[15] Amer Fdn AIDS Res, New York, NY USA
关键词
HIV; antiretroviral treatment; observational database; Asia and the Pacific;
D O I
10.1097/01.qai.0000145351.96815.d5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Relatively little is known regarding HIV disease natural history and response to antiretroviral treatments among Asian people infected with HIV The Therapeutics Research, Education, and AIDS Training in Asia (TREAT Asia) HIV Observational Database (TAHOD) is a recently established collaborative observational cohort study that aims to assess HIV disease natural history in treated and untreated patients in the Asia-Pacific region. Methods: Observational data are collected on HIV-infected patients from 11 sites in the Asia-Pacific region. Data are centrally aggregated for analyses, with the first baseline and retrospective data transferred in September 2003. Retrospective data were analyzed to assess the response to highly active antiretroviral treatment (HAART) over a 6-month period in terms of changes in CD4 count and proportions of patients achieving an undetectable HIV viral load (<400 copies/mL). Results: By the end of May 2004, 1887 patients had been recruited to the TAHOD. Seventy-two percent of patients were male, with median age 36 years. Seventy-eight percent of patients reported HIV infection through heterosexual contact. Forty-three percent of patients had a previous AIDS diagnosis, of whom 55% had tuberculosis. The mean 6-month CD4 count increase was 115 cells/muL (SD = 127) after starting triple-combination therapy. Smaller CD4 count increases were associated with a higher CD4 count before starting treatment, prior treatment with monotherapy or double therapy, and treatment with a HAART regimen containing a nucleoside reverse transcriptase inhibitor (NRTI) and/or protease inhibitor (PI) but without a non-nucleoside reverse transcriptase inhibitor (NNRTI). Five hundred and ninety-eight patients started HAART and had a viral load assessment at 6 months, with 69% attaining an undetectable viral load. Older patients, patients not exposed to HIV through heterosexual contact, and patients treated with HAART containing NRTIs and NNRTIs but without PIs were found to be more likely to achieve an undetectable level. Conclusion: Analyses of retrospective data in the TAHOD suggest that the overall response to HAART in Asian populations is similar to that seen in Western countries.
引用
收藏
页码:174 / 179
页数:6
相关论文
共 15 条
[1]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[2]   A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study [J].
Carr, A ;
Chuah, J ;
Hudson, J ;
French, M ;
Hoy, J ;
Law, M ;
Sayer, D ;
Emery, S ;
Cooper, DA .
AIDS, 2000, 14 (09) :1171-1180
[3]   HIV/AIDS in New Zealand: An epidemic in decline? [J].
Sharples, KJ ;
Dickson, NP ;
Paul, C ;
Skegg, DCG .
AIDS, 1996, 10 (11) :1273-1278
[4]  
*EF VIP COH GROUP, 2004, J ACQ IMMUN DEF SYND, V35, P343
[5]   Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies [J].
Egger, M ;
May, M ;
Chêne, G ;
Phillips, AN ;
Ledergerber, B ;
Dabis, F ;
Costagliola, D ;
Monforte, AD ;
de Wolf, F ;
Reiss, P ;
Lundgren, JD ;
Justice, AC ;
Staszewski, S ;
Leport, C ;
Hogg, RS ;
Sabin, CA ;
Gill, MJ ;
Salzberger, B ;
Sterne, JAC .
LANCET, 2002, 360 (9327) :119-129
[6]  
French Martyn, 2002, HIV Clin Trials, V3, P177
[7]  
GALAI N, 1995, J ACQ IMMUN DEF SYND, V8, P66
[8]   Changing demographics in an HIV-infected population: Results from an observational cohort study in western Denmark [J].
Jensen-Fangel, S ;
Pedersen, C ;
Larsen, CS ;
Tauris, P ;
Moller, A ;
Obel, N .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2001, 33 (10) :765-770
[9]   Natural history of human immunodeficiency virus disease in southern India [J].
Kumarasamy, N ;
Solomon, S ;
Flanigan, TP ;
Hemalatha, R ;
Thyagarajan, SP ;
Mayer, KH .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (01) :79-85
[10]   The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users [J].
Lyles, CM ;
Margolick, JB ;
Astemborski, J ;
Graham, NMH ;
Anthony, JC ;
Hoover, DR ;
Vlahov, D .
AIDS, 1997, 11 (10) :1255-1262